Cargando…

Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents

MET is a receptor tyrosine kinase known for its pleiotropic effects in tumorigenesis. Dysregulations of MET expression and/or signaling have been reported and determined to be associated with inferior outcomes in breast cancer patients rendering MET a versatile candidate for targeted therapeutic int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayoub, Nehad M, Al-Shami, Kamal M, Alqudah, Mohammad A, Mhaidat, Nizar M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634371/ https://www.ncbi.nlm.nih.gov/pubmed/29042798 http://dx.doi.org/10.2147/OTT.S148604

Ejemplares similares

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Simvastatin enhances irinotecan-induced apoptosis in prostate cancer via inhibition of MCL-1
por: Alqudah, Mohammad A.Y., et al.
Publicado: (2018)

A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies
por: Piha-Paul, Sarina A, et al.
Publicado: (2021)

Enhancing the Radiation Response in KRAS Mutant Colorectal Cancers Using the c-Met Inhibitor Crizotinib()()()
por: Cuneo, Kyle C., et al.
Publicado: (2018)

Olive Phenolics as c-Met Inhibitors: (-)-Oleocanthal Attenuates Cell Proliferation, Invasiveness, and Tumor Growth in Breast Cancer Models
por: Akl, Mohamed R., et al.
Publicado: (2014)

Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
por: Ayoub, Nehad M, et al.
Publicado: (2019)

The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program
por: Aparicio, Thomas, et al.
Publicado: (2021)

Effect of metformin on irinotecan-induced cell cycle arrest in colorectal cancer cell lines HCT116 and SW480
por: Khader, Esra’a I., et al.
Publicado: (2021)

Novel glyoxalase-I inhibitors possessing a “zinc-binding feature” as potential anticancer agents
por: Al-Balas, Qosay A, et al.
Publicado: (2016)

Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells
por: Schroeder, Rebecca D., et al.
Publicado: (2017)

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary
por: Palma, Norma A., et al.
Publicado: (2014)

Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration
por: Drilon, Alexander, et al.
Publicado: (2020)

Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches
por: Ayoub, Nehad M., et al.
Publicado: (2022)

Primary health care policy and vision for community pharmacy and pharmacists in Jordan
por: Basheti, Iman A., et al.
Publicado: (2020)

Crizotinib Exhibits Antitumor Activity by Targeting ALK Signaling not c-MET in Pancreatic Cancer
por: Yan, Hong Hua, et al.
Publicado: (2014)

Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2023)

Crizotinib‐based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation
por: Chen, Jin‐Jiao, et al.
Publicado: (2023)

Evaluation of Chemotherapeutic Agents
por: Engstrom, W. W.
Publicado: (1949)

Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14–Mutant NSCLC
por: Cravero, Paola, et al.
Publicado: (2020)

Advanced hepatocellular carcinoma with MET-amplified contained excellent response to crizotinib: a case report
por: Gu, Yangjun, et al.
Publicado: (2023)

Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells
por: Pichot, C S, et al.
Publicado: (2009)

Accidental Overdose of Multiple Chemotherapeutic Agents
por: Kim, In Soon, et al.
Publicado: (1989)

Anesthesia Medications and Interaction with Chemotherapeutic Agents
por: Watson, Jeremy, et al.
Publicado: (2021)

cMET inhibitor crizotinib impairs angiogenesis and reduces tumor burden in the C3(1)-Tag model of basal-like breast cancer
por: Cozzo, Alyssa J., et al.
Publicado: (2016)

Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition
por: Megiorni, Francesca, et al.
Publicado: (2015)

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
por: Chen, Rui-Lian, et al.
Publicado: (2018)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017)

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib
por: Chen, Yan, et al.
Publicado: (2022)

Complex interactions of lovastatin with 10 chemotherapeutic drugs: a rigorous evaluation of synergism and antagonism
por: Khandelwal Gilman, Kaitlyn A., et al.
Publicado: (2021)

In vitro sensitivity of human ovarian tumours to chemotherapeutic agents.
por: Wilson, A. P., et al.
Publicado: (1981)

A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth
por: MARCHION, DOUGLAS C., et al.
Publicado: (2013)

A case report of response to crizotinib in chemotherapy-refractory metastatic gallbladder cancer with met amplification and acquired resistance resulting from the loss of MET amplification
por: Sun, Hongna, et al.
Publicado: (2021)

Comparison of in vitro activity of epipodophyllotoxins with other chemotherapeutic agents in human medulloblastomas.
por: Tomlinson, F. H., et al.
Publicado: (1991)

Anti-Invasive and Anti-Proliferative Synergism between Docetaxel and a Polynuclear Pd-Spermine Agent
por: Batista de Carvalho, Ana L. M., et al.
Publicado: (2016)

(−)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo
por: Siddique, Abu Bakar, et al.
Publicado: (2019)

Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells
por: Boulos, Joelle C., et al.
Publicado: (2021)

The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance
por: Huang, Xing, et al.
Publicado: (2019)

The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC
por: Huang, Xing
Publicado: (2018)

Effective treatment of MET-amplified non-small cell lung cancer patients with crizotinib: a case description
por: Tang, Mingyue, et al.
Publicado: (2023)

The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
por: Jóri, Balázs, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fv9v4kc32ofe4gr4n4svvnu475